Ticagrelor is an oral reversibly bound antagonist of P2Y12 adenosine diphosphate receptor, platelet aggregation and thrombus formation thus inhibited in atherosclerotic disease. The summary of product characteristics states that ticagrelor with acetylsalicylic acid is co-administered is atherothrombotic for preventing events in adult patients with acute coronary syndrome than people given as defined ST – segment elevation MI , non-ST-segment elevation MI or unstable angina.

Acute coronary syndromes refer to a group of heart diseases of myocardial infarction in unstable angina, which occurs due to a narrowed coronary arteries. They are usually due to coronary artery disease, where cholesterol-rich deposits, or plaques that form created within the walls of the coronary arteries . This can cause the lead to coronary artery gradually gradually and the blood supply to the heart is affected .Similar PLoS Medicine Perspectives article:Citation: Diamond W, Volpe BT antibody and brain disease: the convergence of immunology and physiology. PLoS Med 3 : E498.

Citation: Emmer BJ, van Grond G, Steup – Beckman CTM, Huizinga TWJ, van Buchem View MA Selective involvement the amygdala in systemic lupus erythematosus. PLoS Open Med 3 : E499.